What's in Bracco Diagnostics, Inc's pipeline?

Bracco Diagnostics, Inc has 18 drugs in our index: 16 marketed, 0 filed, 1 in Phase 3, 1 in Phase 2, 0 in Phase 1.

Which companies overlap with Bracco Diagnostics, Inc's portfolio?

Top competitors by shared drug class: GE Healthcare, Chinese PLA General Hospital, Guerbet, Bayer, Children's Hospital of Philadelphia.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/bracco-diagnostics-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Bracco Diagnostics, Inc — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Bracco Diagnostics, Inc pipeline: 16 marketed, 0 filed, 1 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

16 marketed 0 filed 1 Phase 3 1 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
VISIPAQUE 270	VISIPAQUE 270	marketed	Non-ionic iso-osmolar contrast medium		Diagnostic Imaging
Iopamidol 370 mgI/dL	Iopamidol 370 mgI/dL	marketed	Non-ionic iodinated contrast medium		Diagnostic Imaging
Arm 2 - Magnevist	Arm 2 - Magnevist	marketed
MultiHance 0.1 mmol/kg	MultiHance 0.1 mmol/kg	marketed	Paramagnetic contrast agent; gadolinium-based MRI contrast medium	Water protons in tissue; blood-brain barrier; vascular endothelium	Hematology
MULTIHANCE:	MULTIHANCE:	marketed			Other
ProHance	ProHance	marketed
CardioGen-82	CardioGen-82	marketed
Iopamidol 370	Iopamidol 370	marketed
Isovue 250	Isovue 250	marketed	Iodinated contrast medium (non-ionic)		Diagnostic Imaging
Non ionic contrast media comparator	Non ionic contrast media comparator	marketed	Radiographic contrast agent		Diagnostic Imaging
Magnevist	Magnevist	marketed			Other
MultiHance 0.05 mmol/kg	MultiHance 0.05 mmol/kg	marketed	Gadolinium-based contrast agent	Water proton relaxation (T1 relaxation enhancement)	Diagnostic Imaging

Therapeutic area mix

Diagnostic Imaging · 9
Other · 3
Hematology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

GE Healthcare · 3 shared drug classes
Chinese PLA General Hospital · 2 shared drug classes
Guerbet · 2 shared drug classes
Bayer · 1 shared drug class
Children's Hospital of Philadelphia · 1 shared drug class
Centre Hospitalier Régional Metz-Thionville · 1 shared drug class
Assistance Publique - Hôpitaux de Paris · 1 shared drug class
Acusphere · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Bracco Diagnostics, Inc:

Cite this brief

Drug Landscape (2026). Bracco Diagnostics, Inc — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/bracco-diagnostics-inc. Accessed 2026-06-10.